Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

VS-6063

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
OBJECTIVES KRAS mutations, which occur in approximately 25% of lung adenocarcinoma cases, represent a major unmet clinical need… 
2018
2018
Docetaxel, the standard chemotherapy for metastatic castration‐resistant prostate cancer (CRPC) also enhances the survival of… 
Highly Cited
2018
Highly Cited
2018
ABSTRACT The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of… 
2017
2017
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
AbstractPurpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and… 
  • table 1
  • table 2
  • figure 1
  • table 3
Highly Cited
2015
Highly Cited
2015
SummaryObjective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK… 
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2015
2015
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to… 
2014
2014
5521 Background: Defactinib (VS-6063) is an oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK has been shown to… 
Highly Cited
2013
Highly Cited
2013
BACKGROUND We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the…